Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor - PubMed (original) (raw)

Editorial

Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor

B I Lévy. Ann Oncol. 2009 Feb.

Free article

No abstract available

PubMed Disclaimer

Comment on

• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
  Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Scartozzi M, et al. Ann Oncol. 2009 Feb;20(2):227-30. doi: 10.1093/annonc/mdn637. Epub 2008 Oct 7. Ann Oncol. 2009. PMID: 18842611

Similar articles

• Angiogenesis agents.
  Marcinkiewicz C. Marcinkiewicz C. Curr Pharm Des. 2009;15(4):343-4. doi: 10.2174/138161209787315864. Curr Pharm Des. 2009. PMID: 19199961 No abstract available.
• Nanoparticulate drugs for the manipulation of angiogenesis.
  Millar TM, Kanaras AG. Millar TM, et al. Ther Deliv. 2013 Oct;4(10):1217-9. doi: 10.4155/tde.13.96. Ther Deliv. 2013. PMID: 24116904 No abstract available.
• Angiogenesis inhibitors: what is the clinical future?
  Verheul HM, Pinedo HM. Verheul HM, et al. Prog Drug Res. 2005;63:67-91. doi: 10.1007/3-7643-7414-4_4. Prog Drug Res. 2005. PMID: 16265877 Review. No abstract available.
• Antivascular therapies: targets beyond the vessel wall.
  Temming K, Kok RJ. Temming K, et al. ChemMedChem. 2007 Apr;2(4):433-5. doi: 10.1002/cmdc.200600304. ChemMedChem. 2007. PMID: 17315256 Review. No abstract available.
• The discovery of antiangiogenic molecules: a historical review.
  Ribatti D. Ribatti D. Curr Pharm Des. 2009;15(4):345-52. doi: 10.2174/138161209787315855. Curr Pharm Des. 2009. PMID: 19199962 Review.

Cited by

• Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.
  Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Robinson ES, et al. Semin Nephrol. 2010 Nov;30(6):591-601. doi: 10.1016/j.semnephrol.2010.09.007. Semin Nephrol. 2010. PMID: 21146124 Free PMC article. Review.
• Model-based treatment optimization of a novel VEGFR inhibitor.
  Keizer RJ, Gupta A, Shumaker R, Beijnen JH, Schellens JH, Huitema AD. Keizer RJ, et al. Br J Clin Pharmacol. 2012 Aug;74(2):315-26. doi: 10.1111/j.1365-2125.2012.04197.x. Br J Clin Pharmacol. 2012. PMID: 22295876 Free PMC article.
• VEGF inhibition, hypertension, and renal toxicity.
  Hayman SR, Leung N, Grande JP, Garovic VD. Hayman SR, et al. Curr Oncol Rep. 2012 Aug;14(4):285-94. doi: 10.1007/s11912-012-0242-z. Curr Oncol Rep. 2012. PMID: 22544560 Free PMC article. Review.
• New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging.
  Cadour F, Thuny F, Sourdon J. Cadour F, et al. Front Cardiovasc Med. 2022 Feb 7;9:813883. doi: 10.3389/fcvm.2022.813883. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35198613 Free PMC article. Review.
• Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
  Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Di Costanzo GG, et al. Target Oncol. 2017 Dec;12(6):795-803. doi: 10.1007/s11523-017-0522-5. Target Oncol. 2017. PMID: 28770532

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.